Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-010 in metastatic castration-resistant prostate cancer
NL-OMON54503Phase 3Active, not recruiting
- Sponsor
- Farmaceutische Industrie
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, olaparib, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Farmaceutische Industrie. Primary endpoints: Overall survival and Radiographic progression-free survival. Started Jul 2019; status: active, not recruiting.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON54503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54503.